Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Osteopore Ltd. ( (AU:OSX) ).
Osteopore has signed a two-year distribution agreement to introduce an autologous dentin graft process for dental socket preservation in Singapore, using KometaBio’s Smart Dentin Grinder. The technology converts extracted teeth into graft material within minutes, retaining collagen and growth factors that support bone regeneration and potentially offering advantages over commonly used animal-derived xenografts.
The Singapore deal positions Osteopore to leverage the country as a launchpad into the broader ASEAN and Asia-Pacific dental bone graft market, which is forecast to grow strongly this decade. By adding an autologous dentin solution that may also benefit immune-compromised patients, Osteopore broadens its regenerative dental portfolio and strengthens its positioning in a high-growth segment of the regional healthcare market.
The most recent analyst rating on (AU:OSX) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
More about Osteopore Ltd.
Osteopore Limited is an Australian-Singaporean regenerative medicine company specialising in 3D-printed biomimetic and bioresorbable implants. The company targets applications in bone and tissue regeneration and is increasingly focusing on dental and craniofacial indications across Asia-Pacific markets.
Average Trading Volume: 31,878,288
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$4.1M
For a thorough assessment of OSX stock, go to TipRanks’ Stock Analysis page.